ESC Professional Premium Access

Arrhythmia mechanisms

Event: ESC Congress 2022
Topic: Pathophysiology and Mechanisms
Session type: Moderated ePosters
Date: 26 August 2022
Time: 08:15 - 09:00

Congress Session

7 presentations in this session

The ideal environment for the development of postcardiac surgery atrial fibrillation: evidence for endothelial activation and poor cell-cell interaction.

Speaker: Doctor R. Lopez-Galvez (Murcia, ES)
Thumbnail

Effects of doxorubicin and ibrutinib on atrial arrhythmogenity: ex-vivo assessment in human myocardium

Speaker: Mr Y. Berger (Berlin, DE)
Thumbnail

Pulmonary vein anatomical variants and incidence of atrial fibrillation

Speaker: Doctor R. Gallen (Dublin, IE)
Thumbnail

Identifying proteomic profiles as indicators of disease severity in arrhythmogenic cardiomyopathy

Speaker: Doctor D. Akdis (Zurich, CH)
Thumbnail

Immune status comparison in patients with atrial fibrillation or flutter on the base of arterial hypertension

Speaker: Doctor O. Stasyshena (Kiev, UA)
Thumbnail

"Concealed cardiomyopathy" is an important cause of autopsy-inconclusive sudden cardiac death and diagnosis impacts care of surviving relatives

Speaker: Doctor J. Isbister (Sydney, AU)
Thumbnail

Spectrum of rare and common genetic variants in arrhythmogenic cardiomyopathy

Speaker: Doctor M. Lippi (Milan, IT)
Thumbnail

7 speakers from this session

Doctor Raquel Lopez-Galvez

Virgin of the Arrixaca University Clinical Hospital, Murcia (Spain)
2 followers

Mr Yannic Wanja Berger

Charité - University Medicine Berlin, Berlin (Germany)
0 follower

Doctor Rory Gallen

St Vincent's University Hospital, Dublin (Ireland)
0 follower

Doctor Deniz Akdis

University Heart Center, Zurich (Switzerland)
0 follower

Doctor Oksana Stasyshena

Strazhensku Cardiology Institute, Kiev (Ukraine)
1 follower

Doctor Julia Clair Isbister

Centenary Institute, Sydney (Australia)
1 presentation
0 follower

Doctor Melania Lippi

IRCCS Monzino Cardiology Center, Milan (Italy)
0 follower

This platform is supported by

logo Novo Nordisk